To understand the role of tau in the context of AD per se, tau transgenic models have been developed in C. elegans [30–33], D. melanogaster [34, 35] and mice [36, 37] by overexpression of human wild-type full-length tau [26], tau with mutations that result in frontotemporal lobar degeneration (FTLD) [37], or a tau with a risk factor mutation for AD FTLD such as A152T [32]. This evidence concerns the gene MAPT and Alzheimer disease.